CERo Therapeutics Holdings Inc. has announced the completion of the first cohort in its Phase 1 clinical trial of CER-1236, a cellular immunotherapy candidate for patients with acute myeloid leukemia (AML). According to the company, no dose-limiting toxicities were observed in the initial cohort, and cell expansion consistent with preclinical expectations was reported. The completion of the first cohort allows the study to progress to the next planned dose level, pending regulatory approval. CERo Therapeutics stated that it is currently focused on advancing this dose-escalation trial and is not actively seeking acquisition or partnership opportunities at this time. Clinical results from the study have been collected to date; however, the company did not specify when further results will be presented.